JOIN THE MOVEMENT.
Find out why hospitals choose INTERCEPT® treated platelets
“I saw the devastation that bacterial contamination could cause. It was something that I wanted to make sure would never happen again. When I learned that INTERCEPT® Platelets were available, it was a no-brainer to me to say, okay, we need to adopt this technology.”
Mary Berg, MD
Medical Director, Transfusion Medicine Service
University of Colorado
You may also be interested in View all 
Evaluating Usable Shelf-Life of Pathogen Reduced and LVDS Tested Platelet Components
Assessing Platelet Availability - PR vs LVDS
INTERCEPT® Blood System for Platelets
References:
- Estimate for platelet units treated with the INTERCEPT Blood System is based on the number of kits sold per year. Total apheresis collections in 2021 was ~2.4M (Free RJ et al. Transfusion. 2023;1-11).